About Ochre Bio
Ochre Bio is a Healthcare company based in Oxford (United Kingdom) founded in 2019. Genomic medicines for liver diseases are developed using gene therapies. Ochre Bio has raised $39.73 million across 3 funding rounds from investors including Khosla Ventures, Lifelink Systems and Backed. The company has 11 employees. Its chief executive, as recorded, is Jack Omeara. Ochre Bio offers products and services including RNA Therapies, Genomic Platform, and Validation Platform. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is OCHRE BIO LTD.
Company details
Founded in 2019 in Oxford, United Kingdom, Ochre Bio operates in the biotechnology sector. Genomic medicines are developed to address liver diseases through gene therapies that identify and inactivate over-active genes. These therapies support liver transplantation and help prevent fatty liver conditions. A genetic atlas of the human liver has been created via sequencing technologies, with algorithms employed to analyze resulting data sets for deeper disease insights.
- Headquarters Oxford, United Kingdom
- Employees 11
- SectorsHealthcare
- Email••••••••
- Website ochre-bio.com
- Social LinkedIn X
- Legal Name Ochre Bio Ltd
- Date of Incorporation 04 Nov, 2019
- Jurisdiction OXFORD, ENGLAND
- Net Profit-$13.63 M (USD)as on Dec 31, 2022
- Total Equity Funding$39.73M (USD)
in 3 rounds
- Latest Funding Round$30M (USD), Series A
Oct 2022
- InvestorsKhosla Ventures
& 13 more
- Employee Count11
Products & Services of Ochre Bio
Ochre Bio offers a comprehensive portfolio of products and services, including RNA Therapies, Genomic Platform, and Validation Platform.
Develops treatments for liver diseases using RNA platforms
Analyzes human liver data for therapy discovery
Tests therapies in human systems for disease validation
Funding Insights of Ochre Bio
Ochre Bio has successfully raised a total of $39.73M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $30 million completed in October 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $39.73M
- Total Rounds 3
- Last Round Series A — $30M
- First Round $125,000
(Mar 2020)
- Investors Count 14
All 3 funding rounds of Ochre Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2022 | $30M | Series A | – | Khosla Ventures | |
| Jun 2021 | $9.6M | Seed | – | Khosla Ventures | |
| Mar 2020 | $125,000 | Seed | – | Y Combinator | – |
14 investors in total: 11 institutional and 3 angel.
Investors in Ochre Bio
Ochre Bio has secured backing from 14 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Khosla Ventures, Lifelink Systems and Backed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage startups are funded by this venture capital firm. | 2004 | khoslaventures.com | Menlo Park, United States | |
Venture capital firm providing seed funding and community support to founders | backed.vc | London, United Kingdom | ||
Early-stage venture capital investments in healthcare and biotech are made. | 2017 | apollo.vc | ||
VC and PE firm focused on seed and early stage tech companies | hoxtonventures.com | London, United Kingdom | ||
Investments are focused on healthcare startups addressing age-related conditions. | selvedgeventure.com | |||
Early-stage startups are accelerated via funding and educational programs. | ycombinator.com | Mountain View, United States | ||
Venture capital firm focused on healthcare startups | lifeforcecap.com | San Francisco, United States | ||
Hermes-Epitek is engaged in semiconductor and FPD manufacturing equipment distribution. | hermes-epitek.com.sg | Singapore, Singapore | ||
A magazine dedicated to textiles, providing subscriptions, shops, workshops, and events. | selvedge.org | |||
AixThera is focused on developing impactful therapeutics for patients. | aixthera.com | Dublin, Ireland |
Investor details for Ochre Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ochre Bio
42 people are tracked at Ochre Bio (9 in leadership, 10 in board & advisors, 23 in team); the tracked headcount is 11.
| Name | Role | Group |
|---|---|---|
Quin Wills | CSO & MD | Leadership |
Jack Omeara | CEO | Leadership |
Paul Foster | Acting CFO | Leadership |
Massoud Malang | Head Of IT And Cybersecurity | Leadership |
Kenny Moore | Oxford Research Director | Leadership |
Julian Maller | Head Of Computational Biology | Leadership |
Sarah Batey | Head Of Portfolio Development And Scientific Ops. | Leadership |
Jack Castle | Director, Corporate Strategy & BD | Leadership |
Robert Mart | Associate Director Lead Development, Chemistry | Leadership |
Chas Bountra | Board Member | Board & advisors |
Leanne Hodson | Board Member | Board & advisors |
Sangeeta Bhatia | Board Member | Board & advisors |
Michael Hodges | Board Member | Board & advisors |
Troy Dale | Board Member | Board & advisors |
Eduardo Martins | Board Member | Board & advisors |
Alex K. Shalek | Board Member | Board & advisors |
Eliot Forster | Chairperson | Board & advisors |
Chinwe Ukomadu | Board Member | Board & advisors |
Ness Bermingham | Board Member | Board & advisors |
Stephanie Barnett-Dean | Senior Manager, Group Financial Controller | Team |
22 more people are available in the full profile.
Complete people profiles for Ochre Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Ochre Bio
3 dated milestones of Ochre Bio across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Ochre Bio is founded.
- Funding First funding round of $125K.
- Funding Latest funding round, Series A, of $30.0M.
Web traffic of Ochre Bio
The website of Ochre Bio (ochre-bio.com) receives about 2.6K visits a month.
- Monthly visits2.6K
▼ 9.5% vs previous month
Top companies in Genomics & Gene Therapy Platforms
2 companies that operate in the same segment as Ochre Bio (Genomics & Gene Therapy Platforms) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ochre Bio
Complete news archive for Ochre Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ochre Bio
Ochre Bio was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Ochre Bio is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Jack Omeara is the CEO of Ochre Bio, as recorded in our data.
Ochre Bio is a funded company, having raised a total of $39.73M across 3 funding rounds to date. The company's 1st funding round was a Seed of $125K, raised on Mar 2020.
Ochre Bio has 11 employees.
Founded in 2019 in Oxford, United Kingdom, Ochre Bio operates in the biotechnology sector. Genomic medicines are developed to address liver diseases through gene therapies that identify and inactivate over-active genes. These therapies support liver transplantation and help prevent fatty liver conditions. A genetic atlas of the human liver has been created via sequencing technologies, with algorithms employed to analyze resulting data sets for deeper disease insights.
Ochre Bio offers RNA Therapies, Genomic Platform, and Validation Platform.
Ochre Bio has 14 investors. Key investors include Khosla Ventures, Lifelink Systems, Backed, Apollo Health Ventures, and Hoxton Ventures.
Ochre Bio operates through Ochre Bio Ltd.